A recent study, published in «Cancer Research» magazine, can help in the development of new strategies to slow the growth and recurrence of the most common primary brain cancer, glioblastoma in adults.
Research conducted under the direction of St. Michael's Hospital in Toronto and the Hospital for Sick Children (SickKids), showed that the protein ID1 plays a crucial role in the emergence and growth of the tumor, as well as the impact on the patient's response to chemotherapy. ID1 - a protein that holds the other genes on the activation or repression by binding to their activators or inhibitors. In their work, scientists found that ID1 helps maintain glioblastoma cancer stem cells, making them less susceptible to treatment.
Scientists have discovered that when "off» ID1 protein in laboratory models and human cells, glioblastoma development slowed. "Shutting down" protein was performed using CRISPR technology or drug conventionally used for the treatment of psychosis and Tourette's syndrome - pimozide. Command also discovered that the protein disabling reduced tumor resistance to chemotherapy.
Glioblastoma - aggressive form of brain cancer, which is about 15% of all primary brain tumors. It is difficult to treat. Therapy usually involves a combination of several approaches, but currently there is no effective treatment. The median survival with glioblastoma is less than two years.
However, thanks to a new study, scientists have a chance to increase the effectiveness of existing treatments.
They found that ID1 inhibition slows the progression of tumors glioblastoma, breast adenocarcinoma and melanoma in laboratory models. Moreover, by studying human tissue, they found that the protein makes the cells more resistant to chemotherapy. Disabling this protein using pimozide increased overall survival and led the glioblastoma tumors recur less frequently, less progress and grow more slowly.
"Targeting this protein may be a new and promising strategy for patients with glioblastoma," - said the scientists.